<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03377595</url>
  </required_header>
  <id_info>
    <org_study_id>OBGYN-2017-26339</org_study_id>
    <nct_id>NCT03377595</nct_id>
  </id_info>
  <brief_title>Post C-Section Pain Control Using EXPAREL</brief_title>
  <official_title>Post-cesarean Section Analgesic Safety and Efficacy of EXPAREL (Liposomal Bupivacaine) Infiltration Locally Versus Transversus Abdominis Plane Infiltration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluating the safety and efficacy of EXPAREL (Liposomal Bupivacaine ) for pain control in&#xD;
      patients undergoing scheduled cesarean section by giving it either as infiltration in&#xD;
      Transversus Abdominis Plane after finishing the procedure or through wound infiltration into&#xD;
      the fascia prior to closure of skin&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Lack of resources, no data collected&#xD;
  </why_stopped>
  <start_date type="Actual">July 2, 2019</start_date>
  <completion_date type="Actual">September 1, 2019</completion_date>
  <primary_completion_date type="Actual">August 30, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total opioid consumption</measure>
    <time_frame>72 hours</time_frame>
    <description>Total opioid medication use by patient after having cesarean section</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to first rescue opioid pain medication</measure>
    <time_frame>72 hours</time_frame>
    <description>Time till the patient asks for opioid medication for breakthrough pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of opioid-free subjects</measure>
    <time_frame>24,48, and 72 hours</time_frame>
    <description>Percentage of patients didn't require any opioid medications after the cesarean section</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's satisfaction</measure>
    <time_frame>through 72 hours post-op or at discharge</time_frame>
    <description>Patient's satisfaction questionnaire with pain control</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS (visual analogue scale) pain scores</measure>
    <time_frame>at 6, 12, 18, 24, 30, 36, 42, 48, and 72 hours after surgery</time_frame>
    <description>pain level assessment using visual assessment pain score which ranges from zero for no pain to 10 intolerable pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with EXPAREL related adverse events</measure>
    <time_frame>through day 14 post-op</time_frame>
    <description>side effects of EXPAREL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Allergic reactions attributable to local anesthetic use</measure>
    <time_frame>through day14 post-op</time_frame>
    <description>Such as allergies, rash etc...</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wound complications</measure>
    <time_frame>through day 14 post-op</time_frame>
    <description>cesarean section wound complications like infection, hematoma, and dehiscence</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>TAP (Transversus Abdominis Plane) block</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20-mL dose of EXPAREL 266 mg expanded in volume with 20 mL normal saline plus 20 mL 0.25% bupivacaine for a total volume of 60 mL m.A 2-point classic TAP block will be performed under ultrasound guidance within 1 hour (± 30 minutes) following skin incision closure of the C-section.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Wound infiltration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mL of EXPAREL 266 mg expanded in volume with 40 mL normal saline for a total volume of 60 mL, infiltrated in the fascia prior to skin closure with attention to infiltrate the angles of the incision.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exparel</intervention_name>
    <description>TAP (Transversus Abdominis Plane) block</description>
    <arm_group_label>TAP (Transversus Abdominis Plane) block</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exparel</intervention_name>
    <description>Wound infiltration</description>
    <arm_group_label>Wound infiltration</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Females 18 years of age and older at screening.&#xD;
&#xD;
          2. Term pregnancies of 37 to 42 weeks gestation, scheduled to undergo elective C-section.&#xD;
&#xD;
          3. ASA (American Society of Anesthesiologists) physical status 1, 2, or 3 are able to&#xD;
             provide informed consent, adhere to the study visit schedule, and complete all study&#xD;
             assessments&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Age &lt;18&#xD;
&#xD;
          2. BMI &gt; or equal to 40 or otherwise not anatomically appropriate to undergo a TAP block.&#xD;
&#xD;
          3. Planned general anesthetic&#xD;
&#xD;
          4. Cesarean delivery via vertical skin incision&#xD;
&#xD;
          5. Allergy, hypersensitivity, intolerance, or contraindication to any of the study&#xD;
             medications.&#xD;
&#xD;
          6. Planned concurrent surgical procedure with the exception of salpingo-oophorectomy or&#xD;
             tubal ligation.&#xD;
&#xD;
          7. Severely impaired renal or hepatic function (eg, serum creatinine level &gt;2 mg/dL&#xD;
             [176.8 µmol/L], blood urea nitrogen level &gt;50 mg/dL [17.9 mmol/L], serum aspartate&#xD;
             aminotransferase [AST] level &gt;3 times the upper limit of normal , or serum alanine&#xD;
             aminotransferase [ALT] level &gt;3 times the upper limit of normal.)&#xD;
&#xD;
          8. Subjects at an increased risk for bleeding or a coagulation disorder (defined as&#xD;
             platelet count less than 80, 000 × 103/mm3 or international normalized ratio greater&#xD;
             than 1.5).&#xD;
&#xD;
          9. Concurrent painful physical condition that may require analgesic treatment (such as&#xD;
             long-term, consistent use of opioids) in the postsurgical period for pain that is not&#xD;
             strictly related to the surgery and which may confound the postsurgical assessments.&#xD;
&#xD;
         10. Clinically significant medical disease in either the mother or baby that, in the&#xD;
             opinion of the investigator, would make participation in a clinical study&#xD;
             inappropriate. This includes any psychiatric or other disease in the mother that would&#xD;
             constitute a contraindication to participation in the study or cause the mother to be&#xD;
             unable to comply with the study requirements.&#xD;
&#xD;
         11. History of, suspected, or known addiction to or abuse of illicit drug(s), prescription&#xD;
             medicine(s), or alcohol within the past 2 years.&#xD;
&#xD;
         12. Administration of an investigational drug within 30 days or 5 elimination half-lives&#xD;
             of such investigational drug, whichever is longer, prior to study drug administration,&#xD;
             or planned administration of another investigational product or procedure during the&#xD;
             subject's participation in this study&#xD;
&#xD;
         13. Previous participation in an EXPAREL study.&#xD;
&#xD;
         14. Any clinically significant event or condition uncovered during the surgery (eg,&#xD;
             excessive bleeding, acute sepsis) that might render the subject medically unstable or&#xD;
             complicate the subject's postsurgical course.&#xD;
&#xD;
         15. Initiation of treatment with any of the following medications within 1 month of study&#xD;
             drug administration or if the medication(s) are being given to control pain: selective&#xD;
             serotonin reuptake inhibitors (SSRIs), selective norepinephrine reuptake inhibitors&#xD;
             (SNRIs), gabapentin, pregabalin (Lyrica®), or duloxetine (Cymbalta®). If a subject is&#xD;
             taking one of these medications for a reason other than pain control, she must be on a&#xD;
             stable dose for at least 1 month prior to study drug administration.&#xD;
&#xD;
         16. Use of any of the following medications within the times specified before surgery:&#xD;
             long-acting opioid medication, non-steroidal anti-inflammatory drugs (NSAIDs), or&#xD;
             aspirin (except for low-dose aspirin used for cardioprotection) within 3 days, or any&#xD;
             opioid medication or acetaminophen within 24 hours.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hiba Mustafa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>December 1, 2017</study_first_submitted>
  <study_first_submitted_qc>December 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2017</study_first_posted>
  <last_update_submitted>May 14, 2021</last_update_submitted>
  <last_update_submitted_qc>May 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

